Glenmede Trust Co. NA Lowers Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Glenmede Trust Co. NA lowered its position in HealthEquity, Inc. (NASDAQ:HQY) by 1.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 243,177 shares of the company’s stock after selling 4,043 shares during the quarter. Glenmede Trust Co. NA owned 0.28% of HealthEquity worth $19,904,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in HQY. Mackenzie Financial Corp grew its stake in HealthEquity by 16.0% during the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after buying an additional 325,906 shares during the period. Generate Investment Management Ltd acquired a new stake in HealthEquity in the 2nd quarter valued at $24,184,000. Vaughan Nelson Investment Management L.P. raised its position in HealthEquity by 36.7% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after purchasing an additional 226,563 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of HealthEquity by 924.2% during the second quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock worth $18,983,000 after purchasing an additional 198,718 shares in the last quarter. Finally, Overbrook Management Corp purchased a new stake in shares of HealthEquity in the second quarter worth about $12,284,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insider Buying and Selling

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now owns 54,719 shares of the company’s stock, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frank Corvino sold 1,247 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares of the company’s stock, valued at approximately $387,093.98. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock valued at $884,517 in the last quarter. Company insiders own 2.20% of the company’s stock.

HealthEquity Price Performance

HQY opened at $102.47 on Thursday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $88.75 and its 200 day moving average price is $82.32. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $105.82. The firm has a market cap of $8.95 billion, a price-to-earnings ratio of 85.39, a price-to-earnings-growth ratio of 1.62 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, sell-side analysts expect that HealthEquity, Inc. will post 2.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. BTIG Research lifted their price target on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Barrington Research reiterated an “outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research note on Friday, September 20th. Deutsche Bank Aktiengesellschaft lifted their price objective on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.